Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results
Gilead Sciences (Nasdaq: GILD) announced its Q4 and full-year 2020 results, emphasizing the significant role of Veklury in treating hospitalized COVID-19 patients.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2020.
“Gilead continues to play a central role in the pandemic, with Veklury now treating one in two hospitalized patients in the United States. At the same time, we continue to meet the needs of people living with HIV, cancer, viral hepatitis and other conditions,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “As we head into 2021, we have many additional opportunities to help patients, especially in oncology where Trodelvy, for example has the potential to treat a broad range of cancer types. These new opportunities, together with our continued leadership in antivirals put Gilead on a clear path to growth.”
Financial Results
|
|
Three Months Ended |
|
|
|
Twelve Months Ended |
|
|
||||||||||||
|
|
December 31, |
|
|
|
December 31, |
|
|
||||||||||||
(In millions, except percentages, per share amounts) |
|
2020 |
|
2019 |
|
Change |
|
2020 |
||||||||||||